Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review
Last updated Apr 2, 2026 by ATDb automated enrichment · Connections updated May 3, 2026
Details
Two major biopharmaceutical media accounts currently handled by Omnicom—Bristol Myers Squibb and Gilead Sciences—are in review or set to go into review.